Champions Oncology Inc Stock
€4.90
Your prediction
Pros and Cons of Champions Oncology Inc in the next few years
Pros
Cons
Performance of Champions Oncology Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Champions Oncology Inc | 1.660% | 1.220% | 2.469% | -34.902% | -14.138% | 34.595% | -47.579% |
| Heron Therapeutics Inc. | -0.220% | 5.471% | -31.355% | -64.610% | -37.702% | -50.322% | -95.078% |
| Evolus Inc | -6.990% | 1.099% | 0.000% | -66.847% | -32.477% | -52.208% | -65.607% |
| Sangamo Therapeutics Inc. | 18.000% | -12.659% | -29.343% | -56.626% | -25.243% | -83.840% | -97.492% |
News
U.S. Polo Assn. Supports Division I National Intercollegiate Championship, Showcasing the Future of the Sport of Polo
DI Women's and Men's Finals to be Featured in ‘Breakaway: Polo in College' on ESPN
WEST PALM BEACH, FLA. / ACCESS Newswire / April 2, 2026 / U.S. Polo Assn., the official sports brand of
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy
Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D
HACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology,
3 Dividend Champions to Buy and Hold for Decades
There's a saying on Wall Street that "dividends don't lie." Just about every financial metric can be spun by a company's management, but dividends either arrive in the mail or they don't. Companies


